Published in

Lippincott, Williams & Wilkins, AIDS, Supplement 1(28), p. S35-S46, 2014

DOI: 10.1097/qad.0000000000000084

Links

Tools

Export citation

Search in Google Scholar

Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa.

Journal article published in 2014 by Nk Martin, University of Bristol Bristol bSocial and Mathematical Epidemiology Group London School of Hygiene and Tropical Medicine cDepartment of Health Services Research and Policy London School of Hygiene and Tropical Medicine dDepartment of Infectious Disease Epi aSchool of Social and Community Medicine, Angela Devine, Jeffrey W. Eaton, Eaton Jw, Tb Hallett, Alec Miners, Graham R. Foster ORCID, Foster Gr, Gregory J. Dore, Dore Gj, Philippa J. Easterbrook, Easterbrook Pj, Rosa Legood, Peter Vickerman
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Journal Article; Research Support, Non-U.S. Gov't ; OBJECTIVE: There has been discussion about whether individuals coinfected with HIV and hepatitis C virus (HCV) or hepatitis B virus (HBV) (???30% of all people living with HIV) should be prioritized for early HIV antiretroviral therapy (ART). We assess the relative benefits of providing ART at CD4 count below 500 ???cells/??l or immediate ART to HCV/HIV or HBV/HIV-coinfected adults compared with HIV-monoinfected adults. We evaluate individual outcomes (HIV/liver disease progression) and preventive benefits in a generalized HIV epidemic setting. METHODS: We modeled disease progression for HIV-monoinfected, HBV/HIV-coinfected, and HCV/HIV-coinfected adults for differing ART eligibility thresholds (CD4